Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial

Santhosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, Laura Danielle Wagner, Vera Kadlecek, Michaela Obersriebnig, Romana Hochreiter, Anton Klingler, Julian Larcher‐Senn, Ulla Derhaschnig, Wolfgang Bender, Susanne Eder-Lingelbach, Nicole Bézay